Old Dogs, New Tricks: Revisiting Immune Modulatory Approaches for Myelodysplastic Syndromes
暂无分享,去创建一个
[1] K. Metzeler,et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. , 2018, Blood.
[2] G. Baretton,et al. Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia. , 2018, Blood advances.
[3] L. Arenillas,et al. The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient Cohort , 2017 .
[4] Sheng Wei,et al. Immunodepletion of MDSC By AMV564, a Novel Tetravalent Bispecific CD33/CD3 T Cell Engager Restores Immune Homeostasis in MDS in Vitro , 2017 .
[5] A. Dueck,et al. Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia , 2017, JAMA oncology.
[6] H. Medyouf. The microenvironment in human myeloid malignancies: emerging concepts and therapeutic implications. , 2017, Blood.
[7] N. Cheung,et al. Acute myeloid leukemia targets for bispecific antibodies , 2017, Blood Cancer Journal.
[8] Sheng Wei,et al. Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858 , 2017, Leukemia.
[9] D. Gabrilovich. Myeloid-Derived Suppressor Cells , 2017, Cancer Immunology Research.
[10] J. Cleveland,et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. , 2016, Blood.
[11] G. Garcia-Manero,et al. Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment , 2016 .
[12] Hui Yang,et al. A Phase II Study Evaluating the Combination of Nivolumab (Nivo) or Ipilimumab (Ipi) with Azacitidine in Pts with Previously Treated or Untreated Myelodysplastic Syndromes (MDS) , 2016 .
[13] B. Ebert,et al. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.
[14] G. Mufti,et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] G. Mufti,et al. Autoimmune diseases and myelodysplastic syndromes , 2016, American journal of hematology.
[16] S. H. A. Chen,et al. Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs , 2016, Leukemia.
[17] Michelle C. Chen,et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9 , 2016, Nature Medicine.
[18] J. Piette,et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. , 2016, Rheumatology.
[19] S. Colla,et al. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes , 2015, Leukemia.
[20] L. Hofbauer,et al. Myelodysplasia is in the niche: novel concepts and emerging therapies , 2014, Leukemia.
[21] T. Neogi,et al. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database. , 2014, Cancer epidemiology.
[22] A. Trumpp,et al. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit. , 2014, Cell stem cell.
[23] A. Henn,et al. Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell–Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia , 2014, Molecular Cancer Therapeutics.
[24] Weian Zhao,et al. Mesenchymal Stem Cell Biodistribution, Migration, and Homing In Vivo , 2014, Stem cells international.
[25] R. Kischel,et al. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML. , 2014, Blood.
[26] S. Parmar,et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents , 2013, Leukemia.
[27] Sheng Wei,et al. Induction of myelodysplasia by myeloid-derived suppressor cells. , 2013, The Journal of clinical investigation.
[28] L. Hofbauer,et al. Mesenchymal stromal cells from patients with myelodyplastic syndrome display distinct functional alterations that are modulated by lenalidomide , 2013, Haematologica.
[29] I. Bruns,et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells , 2013, Leukemia.
[30] D. Neuberg,et al. Toll-like receptor alterations in myelodysplastic syndrome , 2013, Leukemia.
[31] Xu Cao,et al. The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine , 2013, Nature Medicine.
[32] L. Hofbauer,et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. , 2012, Experimental hematology.
[33] A. Barrett,et al. Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. , 2012, Seminars in hematology.
[34] J. Maciejewski,et al. Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome , 2012, The Journal of Immunology.
[35] M. Aller,et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications. , 2012, Current molecular medicine.
[36] M. Cazzola,et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.
[37] M. Björkholm,et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] D. Neuberg,et al. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis , 2011, Blood.
[39] A. Ganser,et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. Korkolopoulou,et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion , 2010, Haematologica.
[41] N. Young,et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] T. Gajewski,et al. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. , 2009, Blood.
[43] J. Dick,et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.
[44] R. Pfeiffer,et al. Risks of myeloid malignancies in patients with autoimmune conditions , 2009, British Journal of Cancer.
[45] Srinivas Nagaraj,et al. Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.
[46] G. Mufti,et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). , 2007, Blood.
[47] E. Andreakos,et al. Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes , 2007, Clinical Cancer Research.
[48] P. Greenberg,et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.
[49] A. Barrett,et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. , 2003, Blood.
[50] D. Howard,et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells , 2000, Leukemia.
[51] M. Okada,et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. , 1997, International journal of hematology.
[52] L. Adès,et al. Lenalidomide for the Treatment of MDS , 2018 .
[53] W. Hiddemann,et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism , 2016, Leukemia.
[54] V. Bronte,et al. Myeloid-derived suppressor cells in cancer , 2005 .